Lixte Biotechnology Holdings, Inc. (LIXT) Company Total Revenue

Lixte Biotechnology is advancing oncotherapy through a partnership with the NIH, creating synergy in the development of LB-100 inhibitors. The company's product revenue demonstrates that the metric has reached the level of 0.00. Bioinformatics algorithms for molecular analysis are accelerating growth, while a virtual business model delegating tests to external CRO partners enables efficient management of patents and risks.

LIXT - Lixte Biotechnology Holdings, Inc. Company Revenue over the range 07/04/2022 - 07/06/2026

Analytical breakdowns for Lixte Biotechnology Holdings, Inc. (LIXT)

- stock value and consensus price forecast:

Stock Quotes Lixte Biotechnology, Inc.|LIXT - Price Target Chart

- market capitalization details:

Market Value Lixte Biotechnology Holdings, Inc.|LIXT - Total Company Value

- book value of equity indicators:

Net Assets per Single Share Lixte Biotechnology|LIXT - Company Book Value|Market-to-Book Ratio lixte.com|LIXT - Company Total Assets

- company liabilities and liquidity data:

Debt to Capital Ratio Lixte Biotechnology|LIXT - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Lixte Biotechnology Holdings Inc.|LIXT - Company Total Debt|Debt to Net Assets Ratio Lixte Biotechnology Holdings, Inc.|LIXT - Company Long-Term Liabilities|Amount of Current Liabilities Lixte Biotechnology|Intermediate Coverage Ratio lixte.com

- earnings and market ratios statistics:

LIXT - Net Profit|Expected Net Profit Lixte Biotechnology|LIXT - Price to Earnings Ratio|Future Price to Earnings Multiple lixte.com|LIXT - PEG Multiple|EV/EBITDA Multiple Lixte Biotechnology Holdings, Inc.|LIXT - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Lixte Biotechnology|LIXT - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months lixte.com|LIXT - Earnings per share growth in current year|Net earnings per share growth forecast for next year Lixte Biotechnology

- sales volume and revenue indicators:

LIXT - Revenue and Sales Volume|Company Future Sales Lixte Biotechnology, Inc.|LIXT - Market Cap to Revenue|Market Cap to Projected Revenue Lixte Biotechnology Holdings, Inc.

General company analysis:Lixte Biotechnology, Inc. - LIXT

Mass-produced product of Lixte Biotechnology

The indicator is calculated by aggregating daily cash receipts from product sales, reflecting the actual inflow of liquidity. This metric measures operational efficiency, allowing investors to assess sales consistency and the risk of cash flow gaps. For Lixte Biotechnology (LIXT), revenue volume confirms the stability of chemical substance supplies to global laboratories. By analyzing the company's sales levels, one can gauge the commercial resilience of logistics chains within oncology research.

Competing companies